179 related articles for article (PubMed ID: 21961796)
1. Cost-effectiveness of insulin detemir: a systematic review.
Suh DC; Aagren M
Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):641-55. PubMed ID: 21961796
[TBL] [Abstract][Full Text] [Related]
2. Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis.
Guillermin AL; Samyshkin Y; Wright D; Nguyen T; Villeneuve J
J Med Econ; 2011; 14(2):207-16. PubMed ID: 21361858
[TBL] [Abstract][Full Text] [Related]
3. Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK.
Thalange N; Gundgaard J; Parekh W; Tutkunkardas D
BMJ Open Diabetes Res Care; 2019; 7(1):e000664. PubMed ID: 31543973
[TBL] [Abstract][Full Text] [Related]
4. Basal Insulin Regimens for Adults with Type 1 Diabetes Mellitus: A Cost-Utility Analysis.
Dawoud D; Fenu E; Higgins B; Wonderling D; Amiel SA
Value Health; 2017 Dec; 20(10):1279-1287. PubMed ID: 29241887
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of switching patients with type 2 diabetes from insulin glargine to insulin detemir in Chinese setting: a health economic model based on the PREDICTIVE study.
Yang L; Christensen T; Sun F; Chang J
Value Health; 2012; 15(1 Suppl):S56-9. PubMed ID: 22265068
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden.
Ridderstråle M; Jensen MM; Gjesing RP; Niskanen L
J Med Econ; 2013; 16(4):468-78. PubMed ID: 23384160
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
Ericsson Å; Pollock RF; Hunt B; Valentine WJ
J Med Econ; 2013 Dec; 16(12):1442-52. PubMed ID: 24147661
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective.
Mezquita-Raya P; Darbà J; Ascanio M; Ramírez de Arellano A
Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):587-595. PubMed ID: 28649881
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials.
Palmer AJ; Roze S; Valentine WJ; Smith I; Wittrup-Jensen KU
Curr Med Res Opin; 2004 Nov; 20(11):1729-46. PubMed ID: 15537473
[TBL] [Abstract][Full Text] [Related]
10. Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources.
Heller SR; Frier BM; Hersløv ML; Gundgaard J; Gough SC
Diabet Med; 2016 Apr; 33(4):471-7. PubMed ID: 26179360
[TBL] [Abstract][Full Text] [Related]
11. Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States.
Valentine WJ; Erny-Albrecht KM; Ray JA; Roze S; Cobden D; Palmer AJ
Adv Ther; 2007; 24(2):273-90. PubMed ID: 17565917
[TBL] [Abstract][Full Text] [Related]
12. Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis.
Tricco AC; Ashoor HM; Antony J; Beyene J; Veroniki AA; Isaranuwatchai W; Harrington A; Wilson C; Tsouros S; Soobiah C; Yu CH; Hutton B; Hoch JS; Hemmelgarn BR; Moher D; Majumdar SR; Straus SE
BMJ; 2014 Oct; 349():g5459. PubMed ID: 25274009
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of insulin analogues for diabetes mellitus.
Cameron CG; Bennett HA
CMAJ; 2009 Feb; 180(4):400-7. PubMed ID: 19221353
[TBL] [Abstract][Full Text] [Related]
14. Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice--a case-based evaluation.
Evans M; McEwan P; Foos V
J Med Econ; 2015 Feb; 18(2):96-105. PubMed ID: 25325179
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands.
Valentine WJ; Jendle J; Saraheimo M; Thorsteinsson B; Pollock RF; Lammert M
Diabet Med; 2012 Mar; 29(3):303-12. PubMed ID: 21951030
[TBL] [Abstract][Full Text] [Related]
16. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes.
Borah BJ; Darkow T; Bouchard J; Aagren M; Forma F; Alemayehu B
Clin Ther; 2009 Mar; 31(3):623-31. PubMed ID: 19393853
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer's perspective.
Permsuwan U; Thavorn K; Dilokthornsakul P; Saokaew S; Chaiyakunapruk N
J Med Econ; 2017 Sep; 20(9):991-999. PubMed ID: 28649943
[TBL] [Abstract][Full Text] [Related]
18. Costs associated with long-acting insulin analogues in patients with diabetes.
Alemayehu B; Speiser J; Bloudek L; Sarnes E
Am J Manag Care; 2018 Jul; 24(8 Spec No.):SP265-SP272. PubMed ID: 30020738
[TBL] [Abstract][Full Text] [Related]
19. A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review.
Frier BM; Russell-Jones D; Heise T
Diabetes Obes Metab; 2013 Nov; 15(11):978-86. PubMed ID: 23551900
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective.
Evans M; Wolden M; Gundgaard J; Chubb B; Christensen T
Diabetes Obes Metab; 2014 Apr; 16(4):366-75. PubMed ID: 24373113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
